Investment analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ:TTNP opened at $4.30 on Thursday. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80. The company’s 50 day moving average is $5.59 and its two-hundred day moving average is $6.07.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Compound Interest and Why It Matters When Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Buy Cheap Stocks Step by Step
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
